The FDA's drug approvals database recorded a supplement on 14 September 2026 to an abbreviated new drug application for itraconazole held by Amneal Pharmaceuticals.
A supplement to a generic application is usually an administrative or manufacturing change. The record does not describe a new indication, a new formulation or a safety finding, and nothing here changes how itraconazole should be prescribed.
- This is a US generic application supplement, not a new indication or safety alert
- No change to itraconazole prescribing follows from it
- Indian supply is regulated by CDSCO and is unaffected by this US filing
Why it matters
It is the only regulatory item on this desk today, and it carries no clinical change.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free